41 results about "Deficiency syndrome" patented technology

The invention belongs to the field of medicines, and particularly relates to a traditional Chinese medicine compound for treating chronic obstructive pulmonary disease in a stable phase and application thereof. The traditional Chinese medicine composition is prepared from herba epimedii, rhizoma curculiginis, radix astragali, radix salviae miltiorrhizae, lumbricus, rhizoma dioscoreae nipponicae, radix ophiopogonis, radix scutellariae, radix adenophorae, rhizoma zingiberis, cortex mori radicis, rhizoma pinelliae, rhizoma coptidis and semen ginkgo, can play the main effects of tonifying lung and kidney, reducing phlegm and removing blood stasis, and is applied to the stable phase of the chronic obstructive pulmonary disease; the traditional Chinese medicine composition has a good clinical application effect in treatment of chronic obstructive pulmonary diseases, especially lung-kidney qi deficiency syndrome and phlegm-blood stasis syndrome.

The invention discloses a traditional Chinese medicine compound for treating lung-kidney deficiency syndrome stable-phase chronic obstructive pulmonary disease as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine compound comprises the following raw material medicines: 18-22 g of codonopsis pilosula, 9-12 g of morinda officinalis, 12-16 g of radix astragali preparata, 7-11 g of atractylodes macrocephala koidz, 9-11 g of radix rehmanniae preparata, 9-12 g of semen cuscutae, 3-8 g of cassia twig, 10-15 g of salvia miltiorrhiza and 2-6 g of honey-fried ephedra. The traditional Chinese medicine decoction for treating the lung-kidney deficiency syndrome stable-phase chronic obstructive pulmonary disease is obtained by stewing the raw material medicines twice, combining the stewed liquid medicine twice and concentrating the combined liquid medicine. The traditional Chinese medicine compound disclosed by the invention has an excellent treatment effect on the stable-phase chronic obstructive pulmonary disease with the syndrome of deficiency of both lung and kidney, and has better effects of improving exercise tolerance of a patient, relieving clinical symptoms, improving life quality, reducing acute exacerbation times and improving lung functions compared with an existing medicine for treating the disease; meanwhile, the safety is excellent.

The invention belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating liver depression and spleen deficiency syndrome metabolism-related fatty liver disease, which is prepared from the following raw materials in parts by weight: 8 to 10 parts of ginseng, 10 to 15 parts of radix bupleuri, 10 to 15 parts of radix curcumae, 6 to 9 parts of ginger processed pinellia, 6 to 10 parts of fructus amomi, 10 to 15 parts of rhizoma atractylodis, 10 to 15 parts of poria cocos, 10 to 15 parts of semen hoveniae, 10 to 15 parts of radix rehmanniae, 8 to 10 parts of rhizoma polygoni cuspidati and 6 to 9 parts of lignum dalbergiae odoriferae. The traditional Chinese medicine composition is used for treating the metabolism-related fatty liver diseases from the aspects of liver depression, spleen deficiency and phlegm-blood stasis, starts from the core pathological chain of liver depression, spleen deficiency, phlegm-dampness and blood stasis, has the functions of soothing the liver, tonifying the spleen, resolving dampness, reducing fat and promoting blood circulation to remove meridian obstruction, and is particularly suitable for patients with liver depression, spleen deficiency and metabolism-related fatty liver diseases. Clinical tests prove that the traditional Chinese medicine composition has a good treatment effect on patients with liver depression and spleen deficiency syndrome metabolism-related fatty liver diseases, the total effective rate reaches 94% or above, and the traditional Chinese medicine composition is mild in medicine property, good in safety, stable in curative effect, not prone to relapse and suitable for being taken for a long time.

The invention discloses a traditional Chinese medicine composition for treating male asthenospermia and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition comprises prepared rehmannia root, semen cuscutae, raspberry, fructus lycii, schisandra chinensis, semen plantaginis, astragalus membranaceus, Chinese yam, cistanche, herba epimedii and deer-horn glue, the traditional Chinese medicine composition is decocted into decoction or added into boiled honey to be prepared into pills, and the medicine for treating male asthenospermia is obtained. The composition has the advantages of small and precise dosage, small side effect, high safety and low cost. Experimental results show that the traditional Chinese medicine composition can be effectively applied to treatment of male asthenozoospermia due to male kidney essence deficiency, the total effective rate reaches up to 91.67% or above, and the traditional Chinese medicine composition has obvious advantages in improvement of clinical traditional Chinese medicine symptoms compared with western medicines. The invention provides a novel pharmaceutical composition for treating male asthenospermia, and the pharmaceutical composition has practical clinical significance and popularization value.

The invention relates to the technical field of disease animal models, in particular to a construction method, an evaluation method and application of a bipolar affective disorder liver stagnation and spleen deficiency syndrome combined animal model. According to the method, a liver depression and spleen deficiency syndrome modeling method is adopted for model construction, evaluation indexes are formulated by combining manic and depression behavior expressions of mice and innovatively combining typical expressions of liver depression and spleen deficiency, a liver depression and spleen deficiency syndrome animal model evaluation method is explored, and a thought is provided for achieving standardization and normalization of liver depression and spleen deficiency syndrome model evaluation. The modeling method is simple and economical, provides an experimental animal model for syndrome differentiation treatment of diseases, particularly provides a corresponding animal model for traditional Chinese medicine syndrome differentiation treatment and new drug pharmacological experiments, accelerates the progress of traditional Chinese medicine disease syndrome research and new drug development, provides technical service for drug evaluation, and has great application value.

The invention provides a non-invasive real-time detection method and system for characteristic substances of yin and yang deficiency syndromes of a human body, and relates to the technical field of substance detection.The specific scheme includes the steps that an exhaled gas sample containing life substances carrying physiological or pathological information is collected; analyzing the exhaled gas sample based on electrospray extraction ionization mass spectrometry, and marking exhaled gas characteristic molecule information to obtain a yin-yang data set; constructing an initial model by combining a random forest and a gradient boosting decision tree algorithm, training and testing the initial model based on the yin-yang data set to obtain a yin-yang identification model, and associating yin-yang attributes of traditional Chinese medicine diseases with exhaled gas characteristic molecule information; real-time exhaled gas of the subject is obtained, exhaled gas characteristic molecule information is detected, the yin-yang deficiency syndrome is recognized based on the yin-yang recognition model, and a yin-yang deficiency syndrome detection report is obtained and output. The invention aims to solve the problems that the traditional static analysis is difficult to directly distinguish yin and yang of a human body and the accuracy is relatively low by utilizing high-latitude mass spectrum data.

The invention relates to the field of medical health monitoring, and provides a spleen and kidney deficiency syndrome dynamic evaluation system based on a multi-modal biosensor, which comprises a wearable device, and is characterized in that a multi-modal biosensing assembly and an ARM evaluation processor are arranged in the wearable device; the multi-modal biosensing assembly forms a first evaluation table based on sensing difference data of multi-modal sensing data in different acquisition stages within the wearing time of a user; wherein the first evaluation table is used for performing primary and secondary sensing signal scoring on the user according to the sensing difference value data; and the ARM processor is used for constructing a preset spleen and kidney deficiency evaluation model according to the primary and secondary induction scoring signals, and dynamically outputting visual spleen and kidney evaluation information of the user according to the spleen and kidney deficiency evaluation model.

This invention relates to the treatment of glucose transporter type 1 deficiency syndrome (Glut1-DS). In particular, the invention relates to specific medium-chain triglyceride compositions, enriched for C10 (decanoic acid), for use in treating movement disorders in Glut1-DS patients.

The invention discloses a medicinal and edible traditional Chinese medicine composition for postoperative rehabilitation as well as a preparation method and application of the medicinal and edible traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 12 to 27 parts of radix astragali seu hedysari, 2 to 10 parts of radix ginseng, 2 to 10 parts of colla corii asini, 5 to 18 parts of radix angelicae sinensis, 8 to 25 parts of cortex eucommiae, 5 to 18 parts of semen persicae, 23 to 37 parts of small red beans, 8 to 25 parts of pericarpium citri reticulatae, 23 to 37 parts of fructus ziziphi jujubae, 2 to 10 parts of rhizoma zingiberis recens and 8 to 25 parts of semen ziziphi spinosae. The traditional Chinese medicine composition has the effects of tonifying qi and nourishing blood, promoting blood circulation to remove blood stasis and strengthening the spleen and stomach, integrates the effects of tonifying qi and nourishing blood, warming and dredging to remove blood stasis and strengthening the spleen and soothing the nerves in one formula, can cover common deficiency syndrome types, and breaks through the limitation of traditional Chinese medicine individualized dialectical treatment in popularization.

The invention provides a traditional Chinese medicine composition for treating insomnia and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 12-18 parts of spiny jujube seeds, 8-12 parts of platycladus seeds, 8-12 parts of scutellaria baicalensis, 10-14 parts of phellodendron amurense, 7-11 parts of pinellia ternata, 2-4 parts of cinnamon bark, 8-12 parts of bamboo shavings, 7-11 parts of radix polygoni multiflori, 8-12 parts of tangerine peel, 8-12 parts of coix seeds, 8-12 parts of yam, 20-26 parts of tortoise shells and 26-34 parts of raw oysters. The present invention studies the effect of the above-mentioned Chinese medicine composition on the mRNA expression of tryptophan hydroxylase 2 (TPH2), a key protein of the central 5-HT synaptic signaling pathway, and the 5-HIAA content and the 5-HIAA / 5-HT ratio of the 5-HIAA transporter (Slc6a4) in the rat model of insomnia with spleen deficiency syndrome caused by complex factors. The results show that the Chinese medicine composition can up-regulate the mRNA expression of TPH2 and Slc6a4 in the dorsal raphe nucleus of the rat model of insomnia with spleen deficiency syndrome, and up-regulate the 5-HIAA content and the 5-HIAA / 5-HT ratio, thereby finally improving the insomnia symptoms.

The invention discloses a yang-tonifying and tendon-strengthening composition for tonifying spleen and kidney and strengthening muscles and bones and a preparation method of the yang-tonifying and tendon-strengthening composition. The composition for tonifying yang and strengthening tendons is prepared from the following raw materials: 20 to 80g of flos chrysanthemi, 1 to 6g of radix ginseng, 4 to 18g of poria cocos, 1.5 to 8g of rhizoma dioscoreae, 4 to 18g of radix astragali seu hedysari, 2 to 10g of rhizoma atractylodis macrocephalae, 1 to 6g of pericarpium zanthoxyli, 4 to 18g of fructus mori, 4 to 28g of fructus lycii, 3 to 15g of cortex eucommiae, 4 to 28g of radix morindae officinalis, 3 to 15g of semen cuscutae, 4 to 28g of radix rehmanniae praeparata, 2 to 10g of radix rehmanniae recen, 4 to 28g of radix angelicae sinensis and 1.5 to 8g of radix polygalae. Compared with the prior art, the preparation method is improved, flavone components and polysaccharide components in the traditional Chinese medicinal materials are dissolved in the medicament to prepare the yang-tonifying and tendon-strengthening drink or the yang-tonifying and tendon-strengthening pill, the kidney-deficiency syndrome and the lumbago disease caused by kidney deficiency are jointly treated through the principle of monarch, minister, assistant and guide, and creatinine and urea are obviously reduced after the medicament is applied.

The invention discloses a kidney essence deficiency diagnosis model construction and optimization construction method and system, and the method comprises the steps: carrying out the grouping processing of basic clinical information data, and obtaining the baseline data of kidney essence deficiency syndromes; performing standard equalization processing on the kidney essence deficiency syndrome baseline data to obtain kidney essence deficiency syndrome standard data, performing grouping analysis on the kidney essence deficiency syndrome standard data to generate an optimal model training set, and calculating and determining a kidney essence deficiency syndrome score of each group of kidney essence deficiency syndrome standard data after grouping; according to a diagnosis model structure, the kidney essence deficiency syndrome score and the quantification interval of the kidney essence deficiency syndrome score, constructing an initial kidney essence deficiency diagnosis model; and training the initial kidney essence deficiency diagnosis model based on each group of kidney essence deficiency syndrome standard data and the optimal model training set, and obtaining an optimal kidney essence deficiency diagnosis model according to a training result. By applying the method and the system provided by the invention, the diagnosis and prediction level and accuracy of the kidney essence deficiency syndrome are improved.

The invention discloses a TCM syndrome differentiation system for early breast cancer during chemotherapy, including four syndrome types, namely: liver depression and yin deficiency syndrome, corresponding syndrome items are: irritability, thin white tongue coating, forgetfulness, chest and flank distension and pain, dry mouth, hot flashes, chest and abdominal pain, bone pain, abdominal distension, chest tightness; qi and yin deficiency syndrome, corresponding syndrome items are: deep pulse, thin white tongue coating, red tongue, hot flashes, forgetfulness, dry mouth, pale complexion, sore waist and knees, spontaneous sweating, ruddy complexion; spleen deficiency and blood deficiency syndrome, corresponding syndrome items are: pale tongue color, white and greasy tongue coating, pale complexion, dry mouth, poor appetite, thin pulse, fat tongue; qi stagnation and blood stasis syndrome, corresponding syndrome items are: ecchymosis on tongue, blue lips, varicose veins under tongue, stringy pulse, dark complexion, numbness of limbs, oral ulcers. The invention also discloses a construction method and application of the system. The invention provides a theoretical basis for the standardized TCM treatment of patients in the chemotherapy period of early breast cancer, and has broad application prospects.

The invention provides a false symptom patient tongue picture recognition method based on a two-stage graph convolution Mama network, and the method comprises the steps: carrying out the superpixel segmentation of a tongue picture image through employing an SLIC algorithm, and dividing the tongue picture image into B sub-graphs; local aggregation and enhancement of spectral and spatial features in sub-graphs are carried out through a two-stage graph convolution layer and a DSFR module, and an enhanced node feature matrix is obtained; obtaining absolute position information of each sub-graph through an RAPE module, and fusing the absolute position information with the enhanced node feature matrix to obtain a feature embedding sequence of the sub-graphs; performing global spatial feature learning based on a Mama network by taking the feature embedding sequence of the sub-graph as input to obtain a model output feature graph; and performing category mapping on the tongue picture category through MLP to obtain a tongue picture recognition result. According to the method, the classification precision in a complex environment is improved, and the problems of high calculation complexity and information redundancy of a multi-branch model are avoided.

The invention relates to the technical field of medicine, in particular to application of kidney tonifying and asthma relieving decoction in treating asthma, and is technically characterized in that according to the scheme, a bronchial asthma kidney qi deficiency syndrome model is established, a pyroptosis path is utilized, and key inflammatory bodies and inflammatory body related cell factors of the pyroptosis are combined, so that the bronchial asthma kidney qi deficiency syndrome model is established. According to the invention, the mechanism of the kidney-tonifying and asthma-relieving decoction for improving asthma symptoms and intervening the development of the disease course is deeply researched, the mechanism of the kidney-tonifying and asthma-relieving decoction for regulating and controlling the pyroptosis of asthma cells and inhibiting the expression of T cell NLRP3, Caspase 1, Gasdermin family and IL-1beta through an STAT6 / GATA-3 pathway so as to improve the airway inflammation of asthma is provided, and the research on the influence of the kidney-tonifying and asthma-relieving decoction on the pyroptosis signal pathway is developed. The invention can provide a scientific basis for the application of the kidney-tonifying and asthma-relieving decoction to the treatment of asthma, further research the effective target of the kidney-tonifying and asthma-relieving decoction on the molecular level and the essential material basis of the kidney qi deficiency syndrome, and provide a theoretical basis and a new thought for revealing the pathogenesis of asthma and research on the essence of the syndrome.

The present invention relates to the technical field of experimental animal models, and discloses an animal model of lung and spleen qi deficiency syndrome based on the theory of "mother disease and child", and the model realization method includes the following steps: S1, material selection and grouping; S2, model replication; S3, model evaluation; S4, index detection; S5, statistical processing; S6, model verification. The present invention gives model rats a high-fat and low-protein feed, and puts them in a homemade swimming pool to swim to exhaustion after daily weight bearing, and evaluates the model after 6 weeks; the modeling method does not directly damage the lungs of rats, and the spleen qi deficiency process caused by it is very mild, and the onset characteristics of the complex deficiency syndrome course are prolonged, and at the same time, spleen qi deficiency comes first, and lung qi deficiency comes later, which is in line with the basic mechanism of the formation of lung and spleen qi deficiency syndrome in traditional Chinese medicine; the method establishes an animal model of lung and spleen qi deficiency syndrome, and the etiology and pathogenesis are accurate, and it is non-invasive, stable, and easy to evaluate, which broadens the application scope of the original modeling method and lays a foundation for the mechanism research of the method of accompanying soil to produce gold.

The present invention relates to a novel antisense transcript to the human SLC2A1 (Glut1) gene, variants and fragments thereof. This antisense transcript can be used to modulate Glut1 expression and serve to restore Glut1, and as a therapeutic for treating or preventing Glut 1 deficiency syndrome, or other Glut1 related conditions including certain cancers, diabetes, Alzheimer's disease, and retinitis pigmentosa.

The present application relates to the technical field of medicine, and especially relates to a combined Chinese and western medicine composition and application thereof, wherein the combined Chinese and western medicine composition comprises Chinese patent medicine and western medicine; the raw material of the Chinese patent medicine comprises Strychnos seed powder, Earthworm, Codonopsis, Poria cocos, Atractylodes, Chuanxiong, Salvia miltiorrhiza, Panax notoginseng, Radix et Rhizoma Bovis, and Radix Glycyrrhizae; and the effective component of the western medicine is diclofenac; the application of the combined Chinese and western medicine composition in preparation of a lumbar pain medicine; the application is for preparation of intervertebral disc-derived lumbar pain medicines of different syndromes; the syndrome is preferably qi and blood deficiency syndrome; the combined Chinese and western medicine composition can effectively treat intervertebral disc-derived lumbar pain of different syndromes through mutual cooperation between the Chinese patent medicine and the western medicine, and the curative effect is more obvious for intervertebral disc-derived lumbar pain of qi and blood deficiency syndrome.

This invention relates to the treatment of glucose transporter type 1 deficiency syndrome (Glut1-DS). In particular, the invention relates to specific medium-chain triglyceride compositions, enriched for C10 (decanoic acid), for use in treating movement disorders in Glut1-DS patients.

The present invention relates to compositions comprising a methyl group donor compound and an acetyl-CoA donor compound for use in therapy and prevention of diseases associated with dysfunction of mitochondriae, wherein the diseases associated with dysfunction of mitochondriae are nucleotide excision repair deficiency syndromes, especially Xeroderma pigmentosum A, or DNA repair deficiency syndrome ataxia telangiectasia associated with mitochondrial dysfunction. Particularly, the composition is used for therapy of nucleotide excision repair deficiency syndromes, such as Xeroderma pigmentosum A, B, C, D, E, F, G, V, the different forms of Cockayne syndrome (CS), such as Cockayne syndrome type B (CSB) and Cockayne syndrome type A (CSA), and trichothiodystrophy (TTD), or DNA repair deficiency syndrome ataxia telangiectasia associated with mitochondrial dysfunction.

The invention provides application of a mirabilis himalaica (MH) extract in preparation of drugs for tonifying primordial qi, resisting fatigue and preventing and treating deficiency syndromes. The mirabilis himalaica (MH) extract is proved to have excellent anti-fatigue activity through a plurality of fatigue experimental models (such as an exhaustion swimming model, a rotating rod test, a suspension test and a tail suspension test) and in-vivo biochemical index determination thereof. The invention provides application of compounds (such as Boeravinone A, Boeravinone B and Boeravinone E) shown in a formula I in preparation of drugs for tonifying primordial qi, resisting fatigue and preventing and treating deficiency syndromes. A fatigue experiment model and in-vivo biochemical index determination prove that the compound shown in the formula I has excellent anti-fatigue activity.

Use of digestive aid tablets in the preparation of a drug for treating irritable bowel syndrome. The digestive aid tablets consist of Citri Reticulatae Pericarpium, Pseudostellariae Radix, stir-fried Hordei Fructus Germinatus, Crataegi Fructus, and Dioscoreae Rhizoma, and exhibit significant efficacy in the treatment of irritable bowel syndrome with diarrhea and liver qi stagnation and spleen deficiency syndrome.

The application provides a method for screening active ingredients capable of activating TAS1R3 receptors, and belongs to the technical field of screening of active ingredients of traditional Chinese medicines. The application establishes a biosensor, and the biosensor detects the current signal after each concentration of compound solution reacts with the TAS1R3 receptor; the dissociation constant K D of the interaction between the compound and the TAS1R3 receptor is calculated according to the linear fitting equation between the common logarithm of the concentration of the compound and the current change, and the compound with the K D value in the range of 10 ‑13 -10 ‑8 M is screened as the active ingredient capable of activating the TAS1R3 receptor. In the application, the interaction dissociation constant K D of the Atractylodes lactone II and the glycyrrhizic acid with the TAS1R3 protein is 3.759*10 ‑8 M and 4.435*10 ‑9 M respectively, and the binding force with the TAS1R3 protein is very strong. Moreover, the Atractylodes lactone II and the glycyrrhizic acid have the function of improving anemia within a certain concentration, and provide a new idea for the screening of candidate compounds with the sweet characteristic and the treatment of anemia or blood deficiency syndrome in traditional Chinese medicines and the research and development of new drugs.

This invention provides a method for establishing a rat model of COPD to study the medicinal uses and pharmacological effects of Liuwei Buqi Decoction in the treatment of COPD. The traditional Chinese medicines in Liuwei Buqi Decoction are ginseng, astragalus, alpinia oxyphylla, polygonatum odoratum, tangerine peel, and cinnamon. This application provides a basis for the syndrome differentiation and treatment strategy of Liuwei Buqi Decoction by exploring the molecular mechanisms by which Liuwei Buqi Decoction regulates the COPD inflammatory immune network and the molecular mechanisms by which it regulates the lung-gut microecological axis and the inflammatory immune network. Taking the high-incidence syndromes of major diseases during the TCM-advantage stage as a starting point, and based on clinical needs, this study, building upon previous clinical research, uses various techniques such as scRNA-seq, CBA, and metagenomics to explore the molecular mechanism by which Liuwei Buqi Decoction improves airway immune inflammation by regulating the lung microecology in rats with COPD lung-kidney qi deficiency syndrome from the perspective of regulating the lung immune microenvironment and alveolar macrophage polarization. Its mechanism of action was further studied and verified through in vitro experiments.

The application belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating metabolic-related fatty liver disease of liver stagnation and spleen deficiency syndrome, which is composed of the following raw materials by weight: 8-10 parts of ginseng, 10-15 parts of bupleurum, 10-15 parts of curcuma zedoary, 6-9 parts of pinellia, 6-10 parts of amomum, 10-15 parts of atractylodes, 10-15 parts of poria, 10-15 parts of hovenia dulcis, 10-15 parts of rehmannia, 8-10 parts of giant knotweed, and 6-9 parts of olibanum. The traditional Chinese medicine composition treats metabolic-related fatty liver disease from the perspective of liver stagnation and spleen deficiency and phlegm and blood stasis, and starts from the core pathological chain of liver stagnation, spleen deficiency, phlegm and blood stasis, and has the functions of soothing liver and strengthening spleen, removing dampness and fat, and activating blood and dredging collaterals. The traditional Chinese medicine composition is especially suitable for patients with metabolic-related fatty liver disease of liver stagnation and spleen deficiency syndrome. Clinical tests prove that the traditional Chinese medicine composition has good therapeutic effect on patients with metabolic-related fatty liver disease of liver stagnation and spleen deficiency syndrome, and the total effective rate is more than 94%. The traditional Chinese medicine composition has mild medicinal properties, good safety, stable curative effect, and is not easy to relapse, and is suitable for long-term taking.

The present invention relates to a novel antisense transcript to the human SLC2A1 (Glut1) gene, variants and fragments thereof. This antisense transcript can be used to modulate Glut1 expression and serve to restore Glut1, and as a therapeutic for treating or preventing Glut 1 deficiency syndrome, or other Glut1 related conditions including certain cancers, diabetes, Alzheimer's disease, and retinitis pigmentosa.

This invention relates to the treatment of glucose transporter type 1 deficiency syndrome (Glut1-DS). In particular, the invention relates to specific medium-chain triglyceride compositions, enriched for C10 (decanoic acid), for use in treating movement disorders in Glut1-DS patients.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating post-infection irritable bowel syndrome as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 15 parts of rhizoma atractylodis macrocephalae, 10 to 20 parts of radix paeoniae alba, 3 to 7 parts of pericarpium citri reticulatae, 5 to 15 parts of radix saposhnikoviae, 10 to 20 parts of folium microcotis, 10 to 20 parts of plumeria rubra, 5 to 15 parts of kapok, 25 to 35 parts of rhizoma smilacis glabrae and 5 to 15 parts of flos albiziae. Animal experiments show that the traditional Chinese medicine composition can effectively improve diarrhea phenotypes and depressive symptoms of rats with PI-IBS liver depression and spleen deficiency syndromes, relieve high sensitivity of viscera, recover a tight junction structure and a cell desmosome structure of colon, up-regulate cell TJ protein expression, recover Th1 / Th2 immune imbalance of blood, reduce the level of proinflammatory factors (TNF-alpha) in colon tissue, and improve the immunity of the rats. And the levels of LPS, DAO and D-LA in serum are up-regulated. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively treating the liver depression and spleen deficiency syndrome of the irritable bowel syndrome after infection.

The invention discloses a deep learning lingual surface fusion-based method and device for identifying kidney-deficiency syndromes of women in the childbearing age. The method comprises the following steps: inputting collected tongue image and surface image data into a preset kidney-deficiency syndrome identification model of the women in the childbearing age; the kidney-deficiency syndrome identification model for the women in the childbearing period outputs an identification result; the kidney-deficiency syndrome identification model for the women in the childbearing period is obtained by training the determined kidney-deficiency syndrome and non-kidney-deficiency syndrome data as training data of a deep learning network. According to the method for identifying the kidney deficiency syndrome of the female at the childbearing age based on the deep learning lingual-surface fusion, the syndrome identification model of the kidney deficiency syndrome of the female at the childbearing age is constructed by utilizing two kinds of modal information of the tongue image and the surface image and utilizing a leading-edge deep learning technology, so that objective syndrome differentiation can be carried out by utilizing the collected observation information of the tongue image and the surface image, and the identification accuracy of the kidney deficiency syndrome of the female at the childbearing age is improved. Diagnosis and treatment decisions of clinicians are assisted.

According to the RA traditional Chinese medicine syndrome typing based on the protein antibody chip technology and application, the protein antibody chip technology is applied to RA traditional Chinese medicine syndrome typing for the first time, and high-throughput and multi-target detection is achieved. Key markers such as IL-6R and TIMP-2 are found, and the combination of the key markers can remarkably improve the syndrome distinguishing accuracy; compared with single ELISA detection, the protein antibody chip technology can analyze 40 inflammatory factors at the same time, and the efficiency is greatly improved. In combination with bioinformatics, molecular characteristics of the damp-heat blockage syndrome and the liver and kidney deficiency syndrome are disclosed; an objective laboratory basis is provided for traditional Chinese medicine differentiation of RA, and clinical precise typing and individualized treatment are assisted.